Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The exfoliation syndrome in cognitive impairment of cerebrovascular or Alzheimer's type.

Literature DB >> 11401639

The exfoliation syndrome in cognitive impairment of cerebrovascular or Alzheimer's type.

E Linnér¹, V Popovic, C G Gottfries, M Jonsson, M Sjögren, A Wallin.

Abstract

The prevalence of exfoliation syndrome was studied in 39 patients suffering from dementia and cognitive impairment; a positive finding of exfoliation was detected in 11/39 of these patients. A comparison with an age-matched population survey showed that the prevalence of ocular exfoliation and the relative risk were significantly elevated. These results suggested that lesions related to the exfoliative process might be located also in the brain of patients suffering from dementia and cognitive impairment.

Entities: Disease Species

Mesh：

Year: 2001 PMID： 11401639 DOI： 10.1034/j.1600-0420.2001.790314.x

Source DB: PubMed Journal: Acta Ophthalmol Scand ISSN： 1395-3907

Keyword Cloud
Cited

24 in total

1. Cerebrovascular blood flow velocities in pseudoexfoliation.

Authors: Nurşen Yüksel; Yonca Anik; Aysun Kiliç; Vlevent Karabaş; Ali Demirci; Yusuf Cağlar
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2005-08-13 Impact factor: 3.117

2. Pseudoexfoliation syndrome: analysis of systemic comorbidities of 325 PEX-positive patients compared with 911 PEX-negative patients.

Authors: Elizabeth Scharfenberg; Franziska G Rauscher; Petra Meier; Dirk Hasenclever
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2019-08-16 Impact factor: 3.117

Review 3. [PEX syndrome. Clinical diagnosis and systemic manifestations].

Authors: E Scharfenberg; U Schlötzer-Schrehardt
Journal: Ophthalmologe Date: 2012-10 Impact factor: 1.059

4. Asymmetric dimethylarginine is not elevated in exfoliation syndrome but symmetric dimethylarginine is related to exfoliative glaucoma.

Authors: Hillevi Blomster; Tuomo Puustjärvi; Matti Kontkanen; Pirjo Valtonen; Markku Teräsvirta; Hannu Uusitalo
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2007-02 Impact factor: 3.117

5. Elevated aqueous humour tissue inhibitor of matrix metalloproteinase-1 and connective tissue growth factor in pseudoexfoliation syndrome.

Authors: S L Ho; G F Dogar; J Wang; J Crean; Q D Wu; N Oliver; S Weitz; A Murray; P E Cleary; C O'Brien
Journal: Br J Ophthalmol Date: 2005-02 Impact factor: 4.638

6. Aqueous humor and serum erythropoietin levels in patients with pseudoexfoliation syndrome and pseudoexfoliative glaucoma.

Authors: Başak Doğu; Nurşen Yüksel; Mustafa Baki Cekmen; Yusuf Cağlar
Journal: Int Ophthalmol Date: 2010-09-23 Impact factor: 2.031

The exfoliation syndrome in cognitive impairment of cerebrovascular or Alzheimer's type.

1. Cerebrovascular blood flow velocities in pseudoexfoliation.

2. Pseudoexfoliation syndrome: analysis of systemic comorbidities of 325 PEX-positive patients compared with 911 PEX-negative patients.

Review 3. [PEX syndrome. Clinical diagnosis and systemic manifestations].

4. Asymmetric dimethylarginine is not elevated in exfoliation syndrome but symmetric dimethylarginine is related to exfoliative glaucoma.

5. Elevated aqueous humour tissue inhibitor of matrix metalloproteinase-1 and connective tissue growth factor in pseudoexfoliation syndrome.

6. Aqueous humor and serum erythropoietin levels in patients with pseudoexfoliation syndrome and pseudoexfoliative glaucoma.

7. Alzheimer's peptide and serine proteinase inhibitors in glaucoma and exfoliation syndrome.

8. Directed therapy for exfoliation syndrome.

9. Directed Therapy: An Approach to the Improved Treatment of Exfoliation syndrome.

10. The evaluation of vestibular functions in patients with pseudoexfoliation syndrome.